Loading...

Fruman, David A

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentMolecular Biology & Biochem
Address3242 McGaugh Hall
Zot 3900
CA 92697
Phone(949) 824-1947, 2274
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer
    NIH/NCI R21CA209341Jul 15, 2016 - Jun 30, 2018
    Role: Principal Investigator
    Regulation of B cell differentiation by eIF4E
    NIH/NIAID R21AI124146Mar 16, 2016 - Feb 28, 2018
    Role: Principal Investigator
    Combination strategies to enhance therapy for Ph-like B-ALL
    NIH/NICHD R21HD081319Mar 9, 2015 - Feb 28, 2017
    Role: Principal Investigator
    UCI-GPS: UC Irvine Graduate Professional Success
    NIH DP7OD020321Sep 18, 2014 - Aug 31, 2019
    Role: Principal Investigator
    Solving the elusive mechanism of rapamycin action in lymphocytes
    NIH/NIAID R21AI099656Aug 20, 2012 - Jul 31, 2014
    Role: Principal Investigator
    TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
    NIH/NCI R01CA158383Mar 12, 2012 - Feb 28, 2017
    Role: Principal Investigator
    Immunoregulatory effects of novel mTOR inhibitors
    NIH/NIAID R03AI085462Feb 15, 2010 - Jan 31, 2012
    Role: Principal Investigator
    PI3K Signaling in Single Lymphocytes Analyzed by LMS
    NIH/NIAID R21AI057900Apr 1, 2004 - Mar 31, 2007
    Role: Principal Investigator
    Phosphoinositide 3-Kinase Function in Lymphocytes
    NIH/NIAID R01AI050831Jan 1, 2002 - Dec 31, 2007
    Role: Principal Investigator
    A Training Program in Cancer Biology and Therapeutics (CBT)
    NIH/NCI T32CA009054Jul 1, 1980 - Jun 30, 2020
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman D. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 Jun 13; 10(445). PMID: 29899021.
      View in: PubMed
    2. Thompson JM, Alvarez A, Singha MK, Pavesic MW, Nguyen QH, Nelson LJ, Fruman D, Razorenova OV. Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through a HIF-dependent mechanism. Mol Cancer Ther. 2018 May 02. PMID: 29720560.
      View in: PubMed
    3. Karimzadeh A, Scarfone VM, Varady E, Chao C, Grathwohl K, Fathman JW, Fruman D, Serwold T, Inlay MA. The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells. Stem Cells Transl Med. 2018 Mar 15. PMID: 29543389.
      View in: PubMed
    4. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman D, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 2018 Jan 30; 9(8):8027-8041. PMID: 29487712.
      View in: PubMed
    5. Gotesman M, Vo TT, Herzog LO, Tea T, Mallya S, Tasian SK, Konopleva M, Fruman D. mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL. Oncotarget. 2018 Jan 19; 9(5):6562-6571. PMID: 29464092.
      View in: PubMed
    6. Fruman D, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 2017 Aug 10; 170(4):605-635. PMID: 28802037.
      View in: PubMed
    7. Chiu H, Mallya S, Nguyen P, Mai A, Jackson LV, Winkler DG, DiNitto JP, Brophy EE, McGovern K, Kutok JL, Fruman D. The Selective Phosphoinoside-3-Kinase p110d Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Front Immunol. 2017; 8:747. PMID: 28713374.
      View in: PubMed
    8. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman D. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2017 06 01; 127(6):2438. PMID: 28569734.
      View in: PubMed
    9. Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman D. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Mol Cancer Ther. 2017 Sep; 16(9):1942-1953. PMID: 28566433.
      View in: PubMed
    10. Ueki K, Fruman D, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85a and p85ß regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem. 2017 03 31; 292(13):5608. PMID: 28363934.
      View in: PubMed
    11. Fruman D, O'Brien S. Cancer: A targeted treatment with off-target risks. Nature. 2017 02 23; 542(7642):424-425. PMID: 28199308.
      View in: PubMed
    12. Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman D, Honig B, Landry DW, O'Connor OA. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd and CK1e in hematological malignancies. Blood. 2017 01 05; 129(1):88-99. PMID: 27784673.
      View in: PubMed
    13. Pai C, Walsh CM, Fruman D. Context-Specific Function of S6K2 in Th Cell Differentiation. J Immunol. 2016 10 15; 197(8):3049-3058. PMID: 27613697.
      View in: PubMed
    14. Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman D, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. 2016 Aug 23; 7(34):55083-55097. PMID: 27391151.
      View in: PubMed
    15. Hong CA, Cho SK, Edson JA, Kim J, Ingato D, Pham B, Chuang A, Fruman D, Kwon YJ. Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing. ACS Nano. 2016 Sep 27; 10(9):8705-14. PMID: 27472284.
      View in: PubMed
    16. Fruman D. mTOR signaling: new networks for ALL. Blood. 2016 06 02; 127(22):2658-9. PMID: 27257176; PMCID: PMC4891950.
    17. So L, Lee J, Palafox M, Mallya S, Woxland CG, Arguello M, Truitt ML, Sonenberg N, Ruggero D, Fruman D. The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Sci Signal. 2016 05 31; 9(430):ra57. PMID: 27245614.
      View in: PubMed
    18. Lee JS, Vo TT, Fruman D. Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol. 2016 11; 82(5):1213-1228. PMID: 26805380.
      View in: PubMed
    19. Lee JS, Tang SS, Ortiz V, Vo TT, Fruman D. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015 Nov 03; 6(34):35202-17. PMID: 26460954; PMCID: PMC4742099.
    20. Vo TT, Fruman D. INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. Cancer Discov. 2015 Jul; 5(7):697-700. PMID: 26152921; PMCID: PMC4499858.
    21. Beagle BR, Nguyen DM, Mallya S, Tang SS, Lu M, Zeng Z, Konopleva M, Vo TT, Fruman D. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget. 2015 Feb 10; 6(4):2088-100. PMID: 25576920; PMCID: PMC4385838.
    22. Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, Raffatellu M, Fruman D. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25; 111(47):E5076-85. PMID: 25385646; PMCID: PMC4250172.
    23. Walsh CM, Fruman D. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. J Clin Invest. 2014 Sep; 124(9):3688-90. PMID: 25133419; PMCID: PMC4151232.
    24. Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman D. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. PLoS One. 2014; 9(6):e99486. PMID: 24915189; PMCID: PMC4051752.
    25. Zhang Z, Eckert MA, Ali MM, Liu L, Kang DK, Chang E, Pone EJ, Sender LS, Fruman D, Zhao W. DNA-scaffolded multivalent ligands to modulate cell function. Chembiochem. 2014 Jun 16; 15(9):1268-73. PMID: 24803415.
      View in: PubMed
    26. Fruman D, Cantley LC. Idelalisib--a PI3Kd inhibitor for B-cell cancers. N Engl J Med. 2014 Mar 13; 370(11):1061-2. PMID: 24620870; PMCID: PMC4088325.
    27. Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman D. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. PLoS One. 2014; 9(2):e88865. PMID: 24586420; PMCID: PMC3931643.
    28. Fruman D, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014 Feb; 13(2):140-56. PMID: 24481312; PMCID: PMC3994981.
    29. Conley ME, Fruman D. Genetics. Can cancer drugs treat immunodeficiency? Science. 2013 Nov 15; 342(6160):814-5. PMID: 24233715.
      View in: PubMed
    30. Zhang Z, Ali MM, Eckert MA, Kang DK, Chen YY, Sender LS, Fruman D, Zhao W. A polyvalent aptamer system for targeted drug delivery. Biomaterials. 2013 Dec; 34(37):9728-35. PMID: 24044994.
      View in: PubMed
    31. Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman D, Rizzieri DA, Tan SY, Fan H, Chuah CT, Ong ST. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A. 2013 Jun 18; 110(25):E2298-307. PMID: 23737503; PMCID: PMC3690864.
    32. Yea SS, Fruman D. Achieving cancer cell death with PI3K/mTOR-targeted therapies. Ann N Y Acad Sci. 2013 Mar; 1280:15-8. PMID: 23551096; PMCID: PMC3621026.
    33. So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman D. Selective inhibition of phosphoinositide 3-kinase p110a preserves lymphocyte function. J Biol Chem. 2013 Feb 22; 288(8):5718-31. PMID: 23275335; PMCID: PMC3581375.
    34. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman D. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar; 27(3):586-94. PMID: 23090679; PMCID: PMC3593948.
    35. Limon JJ, Fruman D. Akt and mTOR in B Cell Activation and Differentiation. Front Immunol. 2012; 3:228. PMID: 22888331; PMCID: PMC3412259.
    36. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman D, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89. PMID: 22826565; PMCID: PMC3460689.
    37. So L, Fruman D. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J. 2012 Mar 15; 442(3):465-81. PMID: 22364281; PMCID: PMC3539736.
    38. Soyfoo MS, Konno A, Bolaky N, Oak JS, Fruman D, Nicaise C, Takiguchi M, Delporte C. Link between inflammation and aquaporin-5 distribution in submandibular gland in Sjögren's syndrome? Oral Dis. 2012 Sep; 18(6):568-74. PMID: 22320885.
      View in: PubMed
    39. Janes MR, Fruman D. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. Methods Mol Biol. 2012; 821:251-65. PMID: 22125070.
      View in: PubMed
    40. Fruman D, Rommel C. PI3Kd inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 2011 Dec; 1(7):562-72. PMID: 22586681.
      View in: PubMed
    41. Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman D, Edinger AL. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. Biochem J. 2011 Oct 15; 439(2):299-311. PMID: 21767261; PMCID: PMC3454501.
    42. Beagle B, Fruman D. A lipid kinase cousin cooperates to promote cancer. Cancer Cell. 2011 Jun 14; 19(6):693-5. PMID: 21665142; PMCID: PMC3129267.
    43. Yea SS, Fruman D. Cell signaling. New mTOR targets Grb attention. Science. 2011 Jun 10; 332(6035):1270-1. PMID: 21659593.
      View in: PubMed
    44. Casey SC, Nelson EL, Turco GM, Janes MR, Fruman D, Blumberg B. B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR. Mol Endocrinol. 2011 Jun; 25(6):933-43. PMID: 21436254; PMCID: PMC3100607.
    45. Vu C, Fruman D. Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res. 2010 Nov 15; 16(22):5374-80. PMID: 20826559.
      View in: PubMed
    46. Limon JJ, Fruman D. B cell receptor signaling: picky about PI3Ks. Sci Signal. 2010 Aug 10; 3(134):pe25. PMID: 20699473.
      View in: PubMed
    47. Chen J, Limon JJ, Blanc C, Peng SL, Fruman D. Foxo1 regulates marginal zone B-cell development. Eur J Immunol. 2010 Jul; 40(7):1890-6. PMID: 20449867; PMCID: PMC2926184.
    48. Janes MR, Fruman D. Targeting TOR dependence in cancer. Oncotarget. 2010 May; 1(1):69-76. PMID: 20657741.
      View in: PubMed
    49. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman D. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb; 16(2):205-13. PMID: 20072130; PMCID: PMC4017764.
    50. Fruman D. Regulatory subunits of class IA PI3K. Curr Top Microbiol Immunol. 2010; 346:225-44. PMID: 20563711.
      View in: PubMed
    51. Okkenhaug K, Fruman D. PI3Ks in lymphocyte signaling and development. Curr Top Microbiol Immunol. 2010; 346:57-85. PMID: 20563708; PMCID: PMC4499567.
    52. Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC, Alitalo K, Fruman D, Vary CP. Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Dev Dyn. 2009 Oct; 238(10):2670-9. PMID: 19705443; PMCID: PMC2826787.
    53. Oak JS, Chen J, Peralta RQ, Deane JA, Fruman D. The p85beta regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity. 2009 Aug; 42(5):447-58. PMID: 19811262; PMCID: PMC2804088.
    54. Janes MR, Fruman D. Immune regulation by rapamycin: moving beyond T cells. Sci Signal. 2009 Apr 21; 2(67):pe25. PMID: 19383976.
      View in: PubMed
    55. Fruman D, Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev. 2009 Mar; 228(1):253-72. PMID: 19290933.
      View in: PubMed
    56. Alcázar I, Cortés I, Zaballos A, Hernandez C, Fruman D, Barber DF, Carrera AC. p85beta phosphoinositide 3-kinase regulates CD28 coreceptor function. Blood. 2009 Apr 02; 113(14):3198-208. PMID: 19190244; PMCID: PMC2945823.
    57. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman D. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2008 Sep; 118(9):3038-50. PMID: 18704194; PMCID: PMC2515380.
    58. Fabre S, Carrette F, Chen J, Lang V, Semichon M, Denoyelle C, Lazar V, Cagnard N, Dubart-Kupperschmitt A, Mangeney M, Fruman D, Bismuth G. FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J Immunol. 2008 Sep 01; 181(5):2980-9. PMID: 18713968.
      View in: PubMed
    59. Fruman D, Edinger AL. Cancer therapy: staying current with AMPK. Biochem J. 2008 Jun 01; 412(2):e3-5. PMID: 18466113.
      View in: PubMed
    60. de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman D, Kane LP. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. J Immunol. 2008 May 15; 180(10):6518-26. PMID: 18453570; PMCID: PMC2637999.
    61. Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, Sareen P, Yang VW, Kaestner KH, Fruman D. KLF4 is a FOXO target gene that suppresses B cell proliferation. Int Immunol. 2008 May; 20(5):671-81. PMID: 18375530.
      View in: PubMed
    62. Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman D. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochem Soc Trans. 2007 Nov; 35(Pt 5):1109-13. PMID: 17956290; PMCID: PMC2953540.
    63. Donahue AC, Fruman D. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur J Immunol. 2007 Oct; 37(10):2923-36. PMID: 17724683.
      View in: PubMed
    64. Oak JS, Fruman D. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity. 2007 Sep; 40(6):433-41. PMID: 17729037.
      View in: PubMed
    65. Fruman D, Walsh CM. Signal transduction and autoimmunity: introduction. Autoimmunity. 2007 Sep; 40(6):403-4. PMID: 17729032.
      View in: PubMed
    66. Matheu MP, Deane JA, Parker I, Fruman D, Cahalan MD. Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. J Immunol. 2007 Aug 15; 179(4):2261-9. PMID: 17675487.
      View in: PubMed
    67. Fruman D. The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity. Biochem Soc Trans. 2007 Apr; 35(Pt 2):177-80. PMID: 17371231.
      View in: PubMed
    68. Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman D. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood. 2007 Apr 01; 109(7):2894-902. PMID: 17164340; PMCID: PMC1852227.
    69. Donahue AC, Kharas MG, Fruman D. Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. Methods Enzymol. 2007; 434:131-54. PMID: 17954246.
      View in: PubMed
    70. Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman D. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci U S A. 2006 Nov 07; 103(45):16882-7. PMID: 17071741; PMCID: PMC1636548.
    71. Kharas MG, Yusuf I, Scarfone VM, Yang VW, Segre JA, Huettner CS, Fruman D. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood. 2007 Jan 15; 109(2):747-55. PMID: 16954505; PMCID: PMC1785099.
    72. Chen J, Yusuf I, Andersen HM, Fruman D. FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. J Immunol. 2006 Mar 01; 176(5):2711-21. PMID: 16493026.
      View in: PubMed
    73. Cruz R, Hedden L, Boyer D, Kharas MG, Fruman D, Lee-Fruman KK. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. J Leukoc Biol. 2005 Dec; 78(6):1378-85. PMID: 16204634; PMCID: PMC2424256.
    74. Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman D, Thomas SM, Cantley LC. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol. 2005 Apr; 25(7):2593-606. PMID: 15767666; PMCID: PMC1061637.
    75. Kharas MG, Fruman D. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005 Mar 15; 65(6):2047-53. PMID: 15781610.
      View in: PubMed
    76. Zhu X, Hart R, Chang MS, Kim JW, Lee SY, Cao YA, Mock D, Ke E, Saunders B, Alexander A, Grossoehme J, Lin KM, Yan Z, Hsueh R, Lee J, Scheuermann RH, Fruman D, Seaman W, Subramaniam S, Sternweis P, Simon MI, Choi S. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. J Immunol. 2004 Dec 15; 173(12):7141-9. PMID: 15585835.
      View in: PubMed
    77. Donahue AC, Hess KL, Ng KL, Fruman D. Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. Int Immunol. 2004 Dec; 16(12):1789-98. PMID: 15520044.
      View in: PubMed
    78. Hess KL, Donahue AC, Ng KL, Moore TI, Oak J, Fruman D. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. Eur J Immunol. 2004 Nov; 34(11):2968-76. PMID: 15384044.
      View in: PubMed
    79. Fruman D. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr Opin Immunol. 2004 Jun; 16(3):314-20. PMID: 15134780.
      View in: PubMed
    80. Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman D. Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. J Immunol. 2004 Jun 01; 172(11):6615-25. PMID: 15153476.
      View in: PubMed
    81. Yusuf I, Zhu X, Kharas MG, Chen J, Fruman D. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood. 2004 Aug 01; 104(3):784-7. PMID: 15069012.
      View in: PubMed
    82. Donahue AC, Fruman D. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Semin Cell Dev Biol. 2004 Apr; 15(2):183-97. PMID: 15209378.
      View in: PubMed
    83. Fruman D. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochem Soc Trans. 2004 Apr; 32(Pt 2):315-9. PMID: 15046598.
      View in: PubMed
    84. Kharas MG, Deane JA, Wong S, O'Bosky KR, Rosenberg N, Witte ON, Fruman D. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 2004 Jun 01; 103(11):4268-75. PMID: 14976048.
      View in: PubMed
    85. Deane JA, Fruman D. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol. 2004; 22:563-98. PMID: 15032589.
      View in: PubMed
    86. Ueki K, Fruman D, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem. 2003 Nov 28; 278(48):48453-66. PMID: 14504291.
      View in: PubMed
    87. Maeda N, Inoshima Y, Fruman D, Brachmann SM, Fan H. Transformation of mouse fibroblasts by Jaagsiekte sheep retrovirus envelope does not require phosphatidylinositol 3-kinase. J Virol. 2003 Sep; 77(18):9951-9. PMID: 12941905; PMCID: PMC224593.
    88. Yusuf I, Fruman D. Regulation of quiescence in lymphocytes. Trends Immunol. 2003 Jul; 24(7):380-6. PMID: 12860529.
      View in: PubMed
    89. Donahue AC, Fruman D. Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. J Immunol. 2003 Jun 15; 170(12):5851-60. PMID: 12794110.
      View in: PubMed
    90. Gilman AG, Simon MI, Bourne HR, Harris BA, Long R, Ross EM, Stull JT, Taussig R, Bourne HR, Arkin AP, Cobb MH, Cyster JG, Devreotes PN, Ferrell JE, Fruman D, Gold M, Weiss A, Stull JT, Berridge MJ, Cantley LC, Catterall WA, Coughlin SR, Olson EN, Smith TF, Brugge JS, Botstein D, Dixon JE, Hunter T, Lefkowitz RJ, Pawson AJ, Sternberg PW, Varmus H, Subramaniam S, Sinkovits RS, Li J, Mock D, Ning Y, Saunders B, Sternweis PC, Hilgemann D, Scheuermann RH, DeCamp D, Hsueh R, Lin KM, Ni Y, Seaman WE, Simpson PC, O'Connell TD, Roach T, Simon MI, Choi S, Eversole-Cire P, Fraser I, Mumby MC, Zhao Y, Brekken D, Shu H, Meyer T, Chandy G, Heo WD, Liou J, O'Rourke N, Verghese M, Mumby SM, Han H, Brown HA, Forrester JS, Ivanova P, Milne SB, Casey PJ, Harden TK, Arkin AP, Doyle J, Gray ML, Meyer T, Michnick S, Schmidt MA, Toner M, Tsien RY, Natarajan M, Ranganathan R, Sambrano GR. Overview of the Alliance for Cellular Signaling. Nature. 2002 Dec 12; 420(6916):703-6. PMID: 12478301.
      View in: PubMed
    91. Hallmann D, Trümper K, Trusheim H, Ueki K, Kahn CR, Cantley LC, Fruman D, Hörsch D. Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85alpha. J Biol Chem. 2003 Feb 14; 278(7):5099-108. PMID: 12435753; PMCID: PMC3205087.
    92. Ueki K, Fruman D, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol. 2002 Feb; 22(3):965-77. PMID: 11784871; PMCID: PMC133541.
    93. Fruman D, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Semin Immunol. 2002 Feb; 14(1):7-18. PMID: 11884226.
      View in: PubMed
    94. Mauvais-Jarvis F, Ueki K, Fruman D, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest. 2002 Jan; 109(1):141-9. PMID: 11781359; PMCID: PMC150818.
    95. Fruman D, Ferl GZ, An SS, Donahue AC, Satterthwaite AB, Witte ON. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):359-64. PMID: 11756681; PMCID: PMC117565.
    96. Prejean C, Sarma T, Kurnasov O, Usacheva A, Hemmings B, Cantley L, Fruman D, Morrison LA, Buller RM, Colamonici OR. Phosphatidylinositol 3-kinase confers resistance to encephalomyocarditis and herpes simplex virus-induced cell death through the activation of distinct downstream effectors. J Immunol. 2001 Oct 15; 167(8):4553-9. PMID: 11591783.
      View in: PubMed
    97. Fruman D, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, Bronson RT, Kahn CR, Cantley LC. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet. 2000 Nov; 26(3):379-82. PMID: 11062485.
      View in: PubMed
    98. Nishikawa K, Sawasdikosol S, Fruman D, Lai J, Songyang Z, Burakoff SJ, Yaffe MB, Cantley LC. A peptide library approach identifies a specific inhibitor for the ZAP-70 protein tyrosine kinase. Mol Cell. 2000 Oct; 6(4):969-74. PMID: 11090635.
      View in: PubMed
    99. Fruman D, Satterthwaite AB, Witte ON. Xid-like phenotypes: a B cell signalosome takes shape. Immunity. 2000 Jul; 13(1):1-3. PMID: 10933389.
      View in: PubMed
    100. Satterthwaite AB, Willis F, Kanchanastit P, Fruman D, Cantley LC, Helgason CD, Humphries RK, Lowell CA, Simon M, Leitges M, Tarakhovsky A, Tedder TF, Lesche R, Wu H, Witte ON. A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. Proc Natl Acad Sci U S A. 2000 Jun 06; 97(12):6687-92. PMID: 10829070; PMCID: PMC18703.
    101. Lu-Kuo JM, Fruman D, Joyal DM, Cantley LC, Katz HR. Impaired kit- but not FcepsilonRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85alpha gene products. J Biol Chem. 2000 Feb 25; 275(8):6022-9. PMID: 10681597.
      View in: PubMed
    102. Beitz LO, Fruman D, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem. 1999 Nov 12; 274(46):32662-6. PMID: 10551821.
      View in: PubMed
    103. Aksoy IA, Ramsey MJ, Fruman D, Aksoy S, Cantley LC, Tucker JD, Roberts TM. Mouse phosphoinositide 3-kinase p110alpha gene: cloning, structural organization, and localization to chromosome 3 band B. Biochem Biophys Res Commun. 1999 Aug 27; 262(2):438-42. PMID: 10462494.
      View in: PubMed
    104. Fruman D, Snapper SB, Yballe CM, Alt FW, Cantley LC. Phosphoinositide 3-kinase knockout mice: role of p85alpha in B cell development and proliferation. Biochem Soc Trans. 1999 Aug; 27(4):624-9. PMID: 10917654.
      View in: PubMed
    105. Fruman D, Rameh LE, Cantley LC. Phosphoinositide binding domains: embracing 3-phosphate. Cell. 1999 Jun 25; 97(7):817-20. PMID: 10399908.
      View in: PubMed
    106. Gupta N, Scharenberg AM, Fruman D, Cantley LC, Kinet JP, Long EO. The SH2 domain-containing inositol 5'-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling. J Biol Chem. 1999 Mar 12; 274(11):7489-94. PMID: 10066815.
      View in: PubMed
    107. Fruman D, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 1999 Jan 15; 283(5400):393-7. PMID: 9888855.
      View in: PubMed
    108. Scharenberg AM, El-Hillal O, Fruman D, Beitz LO, Li Z, Lin S, Gout I, Cantley LC, Rawlings DJ, Kinet JP. Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. 1998 Apr 01; 17(7):1961-72. PMID: 9524119; PMCID: PMC1170542.
    109. Fruman D, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998; 67:481-507. PMID: 9759495.
      View in: PubMed
    110. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science. 1997 Jun 20; 276(5320):1848-50. PMID: 9188528.
      View in: PubMed
    111. Fruman D, Cantley LC, Carpenter CL. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. Genomics. 1996 Oct 01; 37(1):113-21. PMID: 8921377.
      View in: PubMed
    112. Wesselborg S, Fruman D, Sagoo JK, Bierer BE, Burakoff SJ. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). J Biol Chem. 1996 Jan 19; 271(3):1274-7. PMID: 8576111.
      View in: PubMed
    113. Fruman D, Pai SY, Burakoff SJ, Bierer BE. Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells. Mol Cell Biol. 1995 Jul; 15(7):3857-63. PMID: 7791792; PMCID: PMC230625.
    114. Fruman D, Bierer BE, Benes JE, Burakoff SJ, Austen KF, Katz HR. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol. 1995 Feb 15; 154(4):1846-51. PMID: 7530743.
      View in: PubMed
    115. Fruman D, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol. 1995 Feb; 25(2):563-71. PMID: 7533090.
      View in: PubMed
    116. Holländer GA, Fruman D, Bierer BE, Burakoff SJ. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. Transplantation. 1994 Nov 15; 58(9):1037-43. PMID: 7526495.
      View in: PubMed
    117. Fruman D, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J. 1994 Apr 01; 8(6):391-400. PMID: 7513288.
      View in: PubMed
    118. Dutz JP, Fruman D, Burakoff SJ, Bierer BE. A role for calcineurin in degranulation of murine cytotoxic T lymphocytes. J Immunol. 1993 Apr 01; 150(7):2591-8. PMID: 7681074.
      View in: PubMed
    119. Fruman D, Mather PE, Burakoff SJ, Bierer BE. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. Eur J Immunol. 1992 Oct; 22(10):2513-7. PMID: 1382988.
      View in: PubMed
    120. Kaye RE, Fruman D, Bierer BE, Albers MW, Zydowsky LD, Ho SI, Jin YJ, Castells MC, Schreiber SL, Walsh CT. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8542-6. PMID: 1382293; PMCID: PMC49956.
    121. Bierer BE, Jin YJ, Fruman D, Calvo V, Burakoff SJ. FK 506 and rapamycin: molecular probes of T-lymphocyte activation. Transplant Proc. 1991 Dec; 23(6):2850-5. PMID: 1721296.
      View in: PubMed
    122. Perkins DL, Wang YS, Fruman D, Seidman JG, Rimm IJ. Immunodominance is altered in T cell receptor (beta-chain) transgenic mice without the generation of a hole in the repertoire. J Immunol. 1991 May 01; 146(9):2960-4. PMID: 1826701.
      View in: PubMed